Kelemen, E
June 1970
British Medical Journal;6/20/1970, Vol. 2 Issue 5711, p733
Academic Journal
No abstract available.


Related Articles

  • Clinical studies of thrombopoietin begin. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;04/25/97, Vol. 10 Issue 4, p29 

    Looks into the development of thrombopoietin in accelerating platelet recovery and other applications. Past research into thrombopoietin; Key issue in this development; Results of the first clinical report of the use of thrombopoetin.

  • Thrombopoietin-Receptor Agonists for Primary Immune Thrombocytopenia. Imbach, Paul; Crowther, Mark // New England Journal of Medicine;8/25/2011, Vol. 365 Issue 8, p734 

    The article discusses the use of thrombopoietin-receptor agonists for the treatment of primary immune thrombocytopenia. Immune thrombocytopenia is a condition which involves immune-mediated destruction of the platelets and impairment in the production of platelets. The levels of thrombopoietin...

  • Thrombopoietin. Kaushansky, Kenneth // New England Journal of Medicine;09/10/98, Vol. 339 Issue 11, p746 

    Focuses on the physiology of thrombopoietin and megakaryocyte production, and how this information can impact the usefulness of thrombopoietin in the treatment of patients with bone marrow failure. Thrombocytopenia in the United States and the units of platelets used annually to reduce the risk...

  • Thrombopoietin--at last. Metcalf, Donald // Nature;6/16/1994, Vol. 369 Issue 6481, p519 

    Studies the platelet-regulatory factor called thrombopoietin. Presence of a humoral factor in the plasma of patients or animals with severe thrombocytopenia; Attempted purification of thrombopoietin from thrombocytopenic plasma; Ability of recombinant thrombopoietin to increase platelet numbers...

  • Clinical use of thrombopoietin. Ottmann, O G; Hoelzer, D; Hofmann, W K // Leukemia (08876924);Sep99, Vol. 13 Issue 9, p1471 

    Discusses the clinical use of thrombopoietin. Effects of thrombopoietin in patients undergoing standard-dose chemotherapy for acute myelogenous leukemia; Factors used for comparison between MGDF and placebo groups.

  • Romiplostim and eltrombopag: in a class of their own.  // Hem/Onc Today;3/10/2009, Vol. 10 Issue 5, p1 

    The article reports on the manner in which the thrombopoietin agents romiplostim and eltrombopag have changed the treatment of chronic adult idiopathic thrombocytopenic purpura.

  • Dasatinib/nilotinib.  // Reactions Weekly;Jan2015, Vol. 1533 Issue 1, p167 

    An abstract of the article "Thrombopoietine receptor agonists are effective to manage thrombocytopenia on TKI-treatment," by M. Fominykh and colleagues is presented.

  • Dexamethasone/hydrocortisone.  // Reactions Weekly;8/24/2013, Issue 1466, p16 

    An abstract of the article "Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy," by A. S. Patil and colleagues is presented.

  • PROMACTA.  // MPR - Residents' Edition;Spring/Summer2009, Vol. 18 Issue 1, pA6 

    The article evaluates the Promacta Thrombopoietin receptor agonist from GlaxoSmithKline.

  • Clinical niche sought for platelet-boosting drugs. Jenks, Susan // JNCI: Journal of the National Cancer Institute;08/21/96, Vol. 88 Issue 16, p1104 

    Focuses on the role of thrombopoietins in boosting blood platelets. Availability issues; Impact on platelet transfusion costs; Stimulation of platelet production.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics